Drug intelligence / Profile preview

ELN-33

Development stage: Preclinical
Lead developer: Elenae Therapeutics
Modality: Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intravitreal

Overview

ELN-33 is an antisense oligonucleotide (ASO) designed as a Locked Nucleic Acid (LNA) mixmer that targets and inhibits microRNA-33a (miR-33a). Developed by Elenae Therapeutics, the drug is intended for the treatment of dry age-related macular degeneration (dry AMD). By antagonizing miR-33a, ELN-33 aims to promote cholesterol efflux and lipid homeostasis within the retinal pigment epithelium, potentially reducing the formation of drusen and slowing disease progression. The program is currently in preclinical development, with data supported by non-human primate (NHP) studies.

Targets

miR-33b (microRNA-33b)

Beyond the preview

Go deeper on ELN-33.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ELN-33.

Explore the full profile